Non-invasive hypertension device sends constant vital sign updates to clinicians.
The U.S. Food and Drug Administration has cleared a new blood pressure monitoring system by San Diego-based medical device company, Sotera Wireless, Inc.
The technology behind the device, which is called the cNIBP — continuous non-invasive blood pressure, is a new feature of the ViSi Mobile wireless patient monitoring system. The device enables clinicians to continuously monitor all of a patient’s vital signs, including beat-to-beat blood pressure, without the use of a catheter or blood pressure cuff. The company said in a statement that physicians can use cNIBP measurements to better manage patients with hypertension.
The company also said that several studies point to the benefits of beat-to-beat blood pressure monitoring, however right now the only way to get accurate continuous data is through a catheter insertion. This is not only uncomfortable, but exposes patients to risk of infection.
Tom Watlington, Sotera chief executive officer, commented that “blood pressure is one of the most important vital signs and yet it is considerably undervalued, largely because most clinicians are limited to periodic cuff-based measurements. By providing data collected around the clock without disrupting a patient’s sleep, we believe the ViSi Mobile System with cNIBP will help improve diagnosis and management of hypertension, saving lives and dollars.”
The ViSi Mobile System is a wrist-worn monitor that measures all core patient vital signs: cNIBP, heart rate or pulse rate, electrocardiogram (ECG), blood oxygenation level, respiration rate, and skin temperature. Wireless technology transmits vital sign data, enabling clinicians to monitor measurements on remote viewing or notification devices. The system incorporates safety features, such as an advanced alarm management system that notifies clinicians of unfavorable changes in a patient’s condition, enabling early intervention if needed.
RESPeRATE is also a non-invasive high blood pressure device cleared by the Food and Drug Administration. The portable computerized device has been clinically proven to lower high blood pressure by guiding the user through sessions of therapeutic breathing. RESPeRATE is used by more than 250,000 men and women worldwide to naturally lower their high blood pressure.